- Market Capitalization, $K 1,182,382
- Shares Outstanding, K 70,338
- Annual Sales, $ 220,180 K
- Annual Income, $ 183,360 K
- 60-Month Beta -0.16
- Price/Sales 5.17
- Price/Cash Flow 5.94
- Price/Book 2.75
|Period||Period Low||Period High||Performance|
| || |
+1.67 (+11.03%)since 11/01/23
| || |
-0.95 (-5.35%)since 09/01/23
| || |
-0.24 (-1.41%)since 12/01/22
The pharmaceutical industry enjoys robust demand irrespective of economic cycles. Also, given its solid growth prospects, I think pharma stocks Pfizer (PFE), Catalyst Pharmaceuticals (CPRX), and Kiniksa...
Following a tumultuous performance year, the biotechnology sector is steadily regaining traction once again, with investors starting to reveal a somewhat bullish sentiment despite having to endure macroeconomic...
The company reported a big jump in revenue and updated guidance.
With the rise of chronic diseases and technological advancements, the pharma market looks poised for substantial expansion. So, fundamentally strong pharma stocks Kiniksa Pharmaceuticals (KNSA), Collegium...
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 0% and 5.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...
Kiniksa Pharmaceuticals, Ltd. (KNSA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...
Centene (CNC) expands the use of Evolent's oncology specialty care to improve cost management.
HCA Midwest, run by HCA Healthcare (HCA), plans to add a two-story medical plaza in Overland Park of $12 million, to be occupied by Family Health Medical Group and Town Plaza Women's Care.
Select Medical (SEM) partners with Lutheran Health Network to enhance critical illness recovery and inpatient rehabilitation services in Fort Wayne and neighborhood communities.
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 125% and 31.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...
|Kiniksa Pharmaceuticals Ltd|
|DWA Healthcare Momentum Invesco ETF|
|Virtus Lifesci Biotech Products ETF|
|Alps Medical Breakthroughs ETF|
|S&P Biotech SPDR|
|Legg Smallcap Quality Value ETF|
|3rd Resistance Point||17.87|
|2nd Resistance Point||17.35|
|1st Resistance Point||17.08|
|1st Support Level||16.29|
|2nd Support Level||15.77|
|3rd Support Level||15.50|